Clinical trial
A Phase 1 Dose Escalation Study of ARQ 197 in Adult Patients With Advanced/Recurrent Solid Tumors
NCT00609921 is registered in ClinicalTrials.gov with Kyowa Kirin Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Dose Escalation Study of ARQ 197 in Adult Patients With Advanced/Recurrent Solid Tumors
- Lead sponsor
- Kyowa Kirin Co., Ltd.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- January 31, 2008
- Completion date
- Not reported
- Enrollment
- 42 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
cancer